Response to PD1 inhibition in conventional chondrosarcoma

Wagner, Michael J.; Ricciotti, Robert W.; Mantilla, José G.; Loggers, Elizabeth T.; Pollack, Seth M.; Cranmer, Lee D.

doi:10.1186/s40425-018-0413-z

Cited by 31 publications

(29 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nivolumab is another PD-1 blocker, which has been the primary focus of several case reports and phase II clinical studies for the treatment of soft tissue sarcoma. It was previously hypothesized that nivolumab may serve a definite role in the treatment of soft tissue sarcoma (13)(14)(15)(16).…”

Section: Discussionmentioning

confidence: 99%

Combination nivolumab and bevacizumab for metastatic myxofibrosarcoma: A case report and review of the literature

2020

View full text Add to dashboard Cite

The main therapeutic strategy for metastatic Myxofibrosarcoma (MFS) is palliative chemotherapy. A number of studies have demonstrated that anti-angiogenic therapy and immunotherapy could improve the survival rate of patients with metastases. However, the effectiveness of the combination of anti-angiogenic therapy and immunotherapy for the therapy of MFS is undetermined. The current study reports a case of metastatic myxofibrosarcoma that was treated with combination Nivolumab (monoclonal antibody, PD-1 inhibitor) and Bevacizumab (monoclonal antibody, anti-VEGF) after progression from the single use of Nivolumab. The aim of the current study is to assess the efficacy and safety of Nivolumab and Bevacizumab for metastatic myxofibrosarcoma and to review the literature. Up to the termination of the follow-up, the patient achieved a partial response for 16 months, had an overall survival for over 29 months since the metastasis and demonstrated a sustained benefit from treatment. The most frequent adverse events were fatigue, abnormality of Alanine aminotransferase (ALT), hypertension and proteinuria. Nivolumab and Bevacizumab treatment indicate beneficial clinical effects and are indicated to be safe to use in patients with metastatic myxofibrosarcoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Combination nivolumab and bevacizumab for metastatic myxofibrosarcoma: A case report and review of the literature

2020

View full text Add to dashboard Cite

show abstract

“…In a phase 2 study evaluating the anti-PD1 antibody nivolumab, one patient with dedifferentiated chondrosarcoma showed partial response [57]. In another report, one patient with metastatic conventional chondrosarcoma treated with nivolumab had a favorable response [58]. There are several trials currently underway evaluating anti-PD1 antibodies in sarcomas including chondrosarcomas.…”

Section: Immune Checkpoint Inhibitorsmentioning

confidence: 99%

Non-Conventional Treatments for Conventional Chondrosarcoma

Monga

Mani

Hirbe

et al. 2020

Cancers

View full text Add to dashboard Cite

Chondrosarcomas are the most common malignant tumors of the cartilage, are seen predominantly in adults, and have varied clinical behavior. The majority of them affect the medullary canal of long bones and pelvic bones. The prognosis of chondrosarcoma is closely related to histological grading; however, the grading is subject to interobserver variability. Conventional chondrosarcomas are overall considered to be chemotherapy- and radiation-resistant, resulting in limited treatment options. The majority of advanced conventional chondrosarcomas are treated with chemotherapy without any survival benefit. Recent studies have evaluated molecular genetic findings which have improved the understanding of chondrosarcoma biology. Newer therapeutic targets are desperately needed. In this review article, we explore ongoing clinical trials evaluating novel ways of treating advanced conventional chondrosarcoma.

show abstract

“…Two of four patients with alveolar soft part sarcoma were reported to have partial response to anti-PD-L1 therapy [18]. A microsatellite instability (MSI), low tumor mutation burden (TMB) chondrosarcoma with 1% PD-L1 positivity, was reported to respond to nivolumab [19]. Finally, the SARC028 clinical trial reported that 18% of patients with mesenchymal tumors had an objective response to pembrolizumab.…”

Section: To the Editormentioning

confidence: 99%